Literature DB >> 1848392

Cost of switching hypertensive patients from enalapril maleate to lisinopril.

E M Lindgren-Furmaga1, A A Schuna, N L Wolff, T L Goodfriend.   

Abstract

The costs and potential savings associated with switching patients in a hypertension clinic from enalapril maleate to lisinopril were analyzed. Patients taking enalapril were randomized to receive lisinopril or to continue taking enalapril. For the 47 patients randomized, data were collected for 25 patients switched to an equal milligram dosage of lisinopril and for 21 patients who continued to receive a constant dosage of enalapril. To maintain blood pressure control, it was necessary to double the dosage of lisinopril in five patients (20%) and have it in one patient (4%), while the enalapril dosage was doubled in two patients (9.5%). The total direct cost of switching patients to lisinopril was $66.33 per patient. The annual drug cost savings per patient for switching to lisinopril would be $52.08, $46.80, and $120.24 for therapy with one 5-, 10-, and 20-mg tablet per day, respectively. A patient would have to receive 15, 17, or 7 months of therapy with 5-, 10-, or 20-mg tablets of lisinopril, respectively, before a net cost savings would be realized. In the evaluation of a less expensive therapeutic alternative, the total cost of switching must be considered.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1848392

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  5 in total

1.  Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.

Authors:  R J Lipsy
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

2.  Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe.

Authors:  Atholl Johnston; Roland Asmar; Björn Dahlöf; Kate Hill; David Albert Jones; Jens Jordan; Michael Livingston; Graham Macgregor; Michael Sobanja; Panagiotis Stafylas; Enrico Agabiti Rosei; José Zamorano
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

Review 3.  Formulary management of ACE inhibitors.

Authors:  K R Gerbrandt; K C Yedinak
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

Review 4.  Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients.

Authors:  H D Langtry; A Markham
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

5.  Effectiveness, safety and cost of drug substitution in hypertension.

Authors:  Atholl Johnston; Panagiotis Stafylas; George S Stergiou
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.